Gen-Probe, Bayer call truce on patent row
This article was originally published in Clinica
San Diego, California-based nucleic acid testing specialist Gen-Probe and Bayer Healthcare are ending their four-year legal wrangle involving multiple patent litigation and contract arbitrations with a settlement that would see the German drugs giant fork out up to $31.7m to its one-time business partner.
You may also be interested in...
Myriad has sold several business units as it narrows its focus to oncology, women's health and mental health diagnostics. CEO Paul Diaz says the moves will allow the company to be a market leader.
US FDA’s Accelerated Approval process has always been a deceptively simple idea. After a three-day public review of ‘dangling’ applications, the underlying complexity remains.
Merck has pulled one Accelerated Approval indication for Keytruda already this year, and a second may have to be withdrawn as well. That will leave the product with 27 indications in the US – unless, of course, more are approved before the AA indications are formally pulled.